Myriad Reports Tumor Bracanalysis CDX Has Identified 44% More Candidates for PARP Therapy
September 29, 2014 at 07:40 AM EDT
Myriad Genetics, Inc. (Nasdaq: MYGN) today announced that its Tumor BRACAnalysis CDx™ companion diagnostic test significantly ...